316 recruiting cholangiocarcinoma (bile duct cancer) trials in July 2026. If you know your FGFR2, IDH1, or HER2 status, our free AI matcher reads your profile (subtype, biomarkers, prior lines, performance status) and ranks trials by how well your eligibility actually fits each protocol — in minutes, no login. Unlike ClinicalTrials.gov filters or NCI's finder, every recruiting trial below has been verified against our live corpus this week, and the biomarker-tiered layout means you don't have to scroll past 200 irrelevant trials to find yours. Start matching →
Current Clinical Trial Landscape
Active research areas in July 2026:
FGFR2 fusion / rearrangement-targeted (14 recruiting trials) — two FDA-approved FGFR inhibitors (pemigatinib, Pemazyre 2020; futibatinib, Lytgobi 2022) in active combinations, plus a wave of next-generation FGFR2-selective inhibitors (TYRA-200, ABSK061, ICP-192) and two registrational Phase 3 tinengotinib trials (NCT05948475, NCT07328919). See the dedicated FGFR2 section below for the full recruiting list — more complete than a manual ClinicalTrials.gov or WHO ICTRP search.
Checkpoint immunotherapy combinations — durvalumab + GemCis is the TOPAZ-1 standard first-line (FDA approved 2022). Trials test rilvegostomig (PD-1 × TIGIT bispecific) + GemCis Phase 3 (NCT07221253, ARTEMIDE-Biliary01), ivonescimab (PD-1/VEGF bispecific) vs FOLFOX (NCT06529718), and SHR-8068 + adebrelimab + chemo Phase 3 (NCT07229625).
HER2-expressing biliary (~5-15% of patients) — T-DXd + rilvegostomig vs SoC Phase 3 (NCT06467357 — the registrational T-DXd biliary trial), zanidatamab (HER2 bispecific, FDA accelerated approval Nov 2024 as Ziihera for HER2+ BTC) + SoC Phase 3 (NCT06282575), trastuzumab + chemo vs chemo alone 1L HER2+ BTC Phase 3 (NCT07062263). Cell-therapy entrant: HER2 × CEA dual-target CAR-NK (NCT07641036).
IDH1 inhibitors (~15% of intrahepatic CCA) — ivosidenib (FDA-approved 2021 as Tibsovo for IDH1-mutated cholangio) + durvalumab + GemCis 1L (NCT06501625), ivosidenib adjuvant (NCT07260175).
Personalized / biomarker-guided — NCT05615818 Personalized Medicine for Advanced Biliary Cancer (Phase 3, biomarker-stratified).
New Phase 3 entrant (July 2026) — D07001 softgel capsule + capecitabine in advanced BTC (NCT06622057).
Standard of care (July 2026): First-line: gemcitabine + cisplatin + durvalumab (TOPAZ-1 regimen). For resectable disease: surgery followed by adjuvant capecitabine (BILCAP). Second-line options depend on biomarkers — FGFR2 fusion+ → futibatinib or pemigatinib; IDH1-mutated → ivosidenib; HER2+ → zanidatamab or T-DXd (off-label per tumor-agnostic data); MSI-H → pembrolizumab; BRAF V600E → dabrafenib + trametinib (off-label, ROAR basket); otherwise FOLFOX.
Subtypes of Cholangiocarcinoma
Cholangiocarcinoma (bile duct cancer) is classified by location, which affects both treatment and trial eligibility:
Intrahepatic (iCCA) — arises within the liver. Most common subtype in trials. Higher rate of FGFR2 fusions (~15%) and IDH1 mutations (~15%). Often grouped with liver cancers.
Perihilar (pCCA / Klatskin tumor) — at the junction of the left and right hepatic ducts. Often locally advanced at diagnosis. Fewer targeted therapy options.
Distal (dCCA) — in the bile duct near the small intestine. May be grouped with pancreatic cancer trials. Surgically resectable more often.
Most trials enroll all subtypes under "biliary tract cancer" (BTC), which also includes gallbladder cancer and ampullary cancer. ClinTrialFinder searches across all these terms automatically.
Key Biomarkers for Trial Eligibility
Molecular profiling is essential for cholangiocarcinoma — several biomarkers have FDA-approved or trial-specific therapies. The FGFR2 fusion / IDH1 mutation / HER2 status results determine which trial-eligibility tier you fall into:
FGFR2 fusion / rearrangement — present in ~15% of intrahepatic CCA. FDA-approved targeted therapy: futibatinib (Lytgobi), pemigatinib (Pemazyre). Multiple combination trials are recruiting: pemigatinib + durvalumab (NCT06728410), pemigatinib + atezolizumab + bevacizumab (NCT06439485), tinengotinib vs physician's choice (NCT05948475 Phase 3), ICP-192 (NCT05678270). For patients with FGFR2 fusion documented on tumor next-generation sequencing or liquid biopsy, these trials are typically the highest-priority match.
IDH1 mutation — present in ~15% of intrahepatic CCA. FDA-approved: ivosidenib (Tibsovo). New trials test combinations with immunotherapy + chemotherapy (NCT06501625 1L ivosidenib + durvalumab + GemCis) and adjuvant use (NCT07260175).
HER2 overexpression / amplification — present in ~5-15% (higher in extrahepatic). Zanidatamab (HER2 × HER2 bispecific) Phase 3 (NCT06282575). Trastuzumab deruxtecan (T-DXd) + rilvegostomig Phase 3 in biliary (NCT06467357) — the registrational T-DXd biliary trial. Trastuzumab + chemo vs chemo alone 1L HER2+ BTC Phase 3 (NCT07062263).
MSI-H / dMMR — rare (~2-3%) but eligible for pembrolizumab (FDA-approved for all MSI-H cancers).
NTRK fusion — very rare but druggable with larotrectinib or entrectinib (FDA-approved).
Comprehensive genomic profiling (e.g., Foundation Medicine, Tempus, Guardant360) is recommended for ALL advanced cholangiocarcinoma patients — at least 30-40% of intrahepatic CCA have an actionable biomarker.
Know your FGFR2, IDH1, or HER2 status? Get matched to bile duct cancer trials in minutes.
🧬 FGFR2 Fusion / Rearrangement in Cholangiocarcinoma — Recruiting Trials (14 trials, the highest-priority biomarker match)
FGFR2 fusions or rearrangements are present in ~15% of intrahepatic cholangiocarcinoma (iCCA) and are the single most actionable biomarker in bile duct cancer. If your tumor next-generation sequencing or ctDNA liquid biopsy shows an FGFR2 fusion, the recruiting trials below are typically the best match. Two FGFR inhibitors are already FDA-approved — pemigatinib (Pemazyre, 2020) and futibatinib (Lytgobi, 2022) — and a wave of next-generation FGFR2-selective inhibitors designed to overcome acquired resistance (the FGFR2 gatekeeper/molecular-brake mutations that limit first-generation drugs) is now recruiting. This is a more complete FGFR2-fusion cholangiocarcinoma recruiting list than a manual ClinicalTrials.gov or WHO ICTRP search returns, because every trial below is verified against our live corpus and filtered to FGFR2-relevant biliary enrollment.
NCT05948475 - Tinengotinib vs Physician's Choice in FGFR-altered cholangiocarcinoma after prior FGFR inhibitor (Phase 3, the registrational tinengotinib trial — tinengotinib is a next-gen multikinase FGFR inhibitor active against resistance mutations)
NCT07328919 - Tinengotinib (TT-00420) vs Chemotherapy in advanced intrahepatic cholangiocarcinoma (Phase 3, second registrational tinengotinib study, activated 2026)
Also opening (not yet recruiting):NCT06530823 pemigatinib + durvalumab in previously-treated biliary tract cancer; NCT07639528 preoperative durvalumab + GemCis ± futibatinib in resectable FGFR2-altered iCCA. Ask your oncologist or use the matcher to be notified when these activate.
NCT06467357 - Trastuzumab Deruxtecan (T-DXd) + Rilvegostomig vs Standard of Care in advanced HER2-expressing biliary tract cancer (Phase 3 — the registrational T-DXd biliary trial)
NCT06282575 - Zanidatamab (HER2 × HER2 bispecific) + SOC vs SOC in 1L HER2+ biliary tract cancer (Phase 3)
NCT07062263 - Trastuzumab + chemotherapy vs chemotherapy alone in first-line HER2-positive advanced BTC (Phase 3)
NCT07641036 - Dual-Target HER2/CEA CAR-NK Cells in advanced biliary tract cancer (Phase 1/2, cell therapy entrant)
First-Line (Treatment-Naive, No Targetable Mutation)
Standard first-line is GemCis + durvalumab (TOPAZ-1 regimen, FDA approved 2022). Trials test additions and alternatives:
NCT07221253 - Rilvegostomig (PD-1 × TIGIT bispecific) or Durvalumab + GemCis in 1L advanced BTC (Phase 3, ARTEMIDE-Biliary01)
How do I find cholangiocarcinoma clinical trials I'm eligible for?
Enter your cholangiocarcinoma details into ClinTrialFinder — including subtype (intrahepatic, perihilar, or distal), biomarkers (FGFR2, IDH1, HER2), and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.
What cholangiocarcinoma trials are currently recruiting?
There are 316 recruiting interventional trials for cholangiocarcinoma / bile duct / biliary tract cancer in July 2026, including FGFR2 fusion-targeted (pemigatinib + durvalumab NCT06728410, pemigatinib + atezo + bev NCT06439485, futibatinib NCT05727176, tinengotinib vs physician's choice NCT05948475 Phase 3, ICP-192 NCT05678270), IDH1-mutated (ivosidenib + durvalumab + GemCis 1L NCT06501625, ivosidenib adjuvant NCT07260175), HER2-expressing (T-DXd + rilvegostomig Phase 3 NCT06467357 — registrational T-DXd biliary trial, zanidatamab Phase 3 NCT06282575, trastuzumab + chemo Phase 3 NCT07062263), 1L immunotherapy combinations (rilvegostomig NCT07221253 Phase 3, SHR-8068 + adebrelimab NCT07229625 Phase 3), bispecific ADCs (BL-B01D1, ivonescimab), CAR-NK cell therapy (HER2/CEA NCT07641036), and D07001 + capecitabine Phase 3 (NCT06622057) for intrahepatic, perihilar, and distal bile duct cancer.
What FGFR2 fusion cholangiocarcinoma trials are recruiting?
There are 14 recruiting FGFR2 fusion / rearrangement cholangiocarcinoma trials in July 2026 — more than a manual ClinicalTrials.gov or WHO ICTRP search typically surfaces. They span three groups: (1) registrational Phase 3 — tinengotinib vs physician's choice (NCT05948475) and tinengotinib TT-00420 vs chemotherapy (NCT07328919), plus HMPL-453 Phase 2/3 (NCT04353375); (2) next-generation FGFR2-selective inhibitors designed to overcome first-generation resistance — TYRA-200 (NCT06160752), ABSK061 (NCT05244551), ICP-192 / gunagratinib (NCT05678270); and (3) FDA-approved FGFR inhibitor combinations — pemigatinib + durvalumab (NCT06728410), pemigatinib + atezolizumab + bevacizumab (NCT06439485), futibatinib (NCT05727176), and the FORTUNE futibatinib basket (NCT04962867). FGFR2 fusions occur in ~15% of intrahepatic cholangiocarcinoma and are the most actionable biomarker in bile duct cancer — confirm your status by tumor NGS or ctDNA, then match to these trials in minutes.
What is the difference between intrahepatic and extrahepatic cholangiocarcinoma?
Intrahepatic cholangiocarcinoma (iCCA) arises within the liver and has the highest rate of targetable mutations (FGFR2 fusions ~15%, IDH1 mutations ~15%). Extrahepatic includes perihilar (Klatskin tumor) and distal cholangiocarcinoma. Most trials enroll all subtypes under "biliary tract cancer" (BTC), but some targeted therapies are primarily studied in intrahepatic CCA.
Should I get molecular profiling for cholangiocarcinoma?
Yes — comprehensive genomic profiling is strongly recommended. Actionable mutations like FGFR2 fusions, IDH1 mutations, HER2 amplification, MSI-H, BRAF V600E, and NTRK fusions each have FDA-approved therapies or active clinical trials. Without profiling, you may miss targeted treatment options.
How is ClinTrialFinder different from ClinicalTrials.gov or NCI's trial finder?
ClinicalTrials.gov and NCI's finder return long lists you filter manually by location and condition. ClinTrialFinder reads your profile (subtype, FGFR2 / IDH1 / HER2 status, prior lines of therapy, performance status) and uses AI to rank trials by how well your individual eligibility matches each protocol — so the trials at the top are the ones you are most likely to actually enroll in. It's free, no login required, and the biomarker-aware match runs in minutes rather than hours of manual filtering.
Find Cholangiocarcinoma Trials Matched to Your Situation
Enter your subtype, biomarkers, and treatment history to get AI-matched trial results in minutes.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.
